Literature DB >> 6260398

Normal and malignant breast tissue is a target organ for 1,25-(0H)2 vitamin D3.

J A Eisman, I Macintyre, T J Martin, R J Frampton, R J King.   

Abstract

Malignant and benign human breast tumours as well as rabbit breast tissue were examined for specific receptors for 1,25-dihydroxyvitamin D3 using competitive binding studies and sucrose density gradient analysis. Classical high affinity, low capacity receptors for 1,25-dihydroxyvitamin D3 were found in breast and node tissue in seven of ten patients with breast cancer and in all three patients with benign neoplasms. An inflammatory breast mass showed no binding. Similar receptors were found in breast tissue from pregnant and lactating rabbits. Taken with other recent data, these results suggest that 1,25-dihydroxyvitamin D3 may activate calcium transport in the malignant as well as in the normal lactating breast.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6260398     DOI: 10.1111/j.1365-2265.1980.tb01053.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  11 in total

1.  Vitamin D receptor expression in colorectal cancer.

Authors:  M G Thomas; P A Sylvester; P Newcomb; R J Longman
Journal:  J Clin Pathol       Date:  1999-03       Impact factor: 3.411

2.  Tumor Expression of Vitamin D Receptor and Breast Cancer Histopathological Characteristics and Prognosis.

Authors:  Jamila Al-Azhri; Yali Zhang; Wiam Bshara; Gary Zirpoli; Susan E McCann; Thaer Khoury; Carl D Morrison; Stephen B Edge; Christine B Ambrosone; Song Yao
Journal:  Clin Cancer Res       Date:  2016-07-12       Impact factor: 12.531

3.  BsmI but not FokI polymorphism of VDR gene is contributed in breast cancer.

Authors:  Shirin Shahbazi; Sara Alavi; Keivan Majidzadeh-A; Massoud Ghaffarpour; Azam Soleimani; Reza Mahdian
Journal:  Med Oncol       Date:  2013-01-01       Impact factor: 3.064

Review 4.  Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy.

Authors:  Donald L Trump; Kristin K Deeb; Candace S Johnson
Journal:  Cancer J       Date:  2010 Jan-Feb       Impact factor: 3.360

5.  Specific binding of 1,25-dihydroxycholecalciferol in human medullary thyroid carcinoma.

Authors:  H C Freake; I MacIntyre
Journal:  Biochem J       Date:  1982-07-15       Impact factor: 3.857

6.  1 alpha-hydroxyvitamin D3, hypercalcemia, and growth suppression of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.

Authors:  Y Iino; M Yoshida; N Sugamata; M Maemura; S Ohwada; T Yokoe; T Ishikita; R Horiuchi; Y Morishita
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

7.  Whole-cell uptake and nuclear localization of 1,25-dihydroxycholecalciferol by breast cancer cells (T47 D) in culture.

Authors:  E Sher; J A Eisman; J M Moseley; T J Martin
Journal:  Biochem J       Date:  1981-11-15       Impact factor: 3.857

8.  Lack of association between vitamin D receptor gene BsmI polymorphism and breast cancer risk: an updated meta-analysis involving 23,020 subjects.

Authors:  Yingying Du; Lixia Hu; Fanliang Kong; Yueyin Pan
Journal:  Tumour Biol       Date:  2013-11-20

9.  Calcitriol and cancer therapy: A missed opportunity.

Authors:  Donald L Trump
Journal:  Bone Rep       Date:  2018-06-13

10.  Vitamin D and Breast Cancer: Mechanistic Update.

Authors:  JoEllen Welsh
Journal:  JBMR Plus       Date:  2021-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.